Ingersoll-Rand (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 8:25 am

Competitors of Ingersoll-Rand (India) Ltd

All Competitor Stocks of Ingersoll-Rand (India) Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:00 am

Below is a detailed analysis of the quarterly data for Ingersoll-Rand (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 315.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Mar 2025) to 315.00 Cr., marking a decrease of 7.00 Cr..
• For Expenses, as of Jun 2025, the value is 241.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 239.00 Cr. (Mar 2025) to 241.00 Cr., marking an increase of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 74.00 Cr., marking a decrease of 9.00 Cr..
• For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 24.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 80.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 10.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 59.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 59.00 Cr., marking a decrease of 9.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 18.68. The value appears to be declining and may need further review. It has decreased from 21.43 (Mar 2025) to 18.68, marking a decrease of 2.75.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:08 am

Growth

Last Updated: September 5, 2025, 7:40 am

Balance Sheet

Last Updated: September 10, 2025, 1:51 pm

Below is a detailed analysis of the balance sheet data for Ingersoll-Rand (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 32.00 Cr..
• For Reserves, as of Mar 2025, the value is 578.00 Cr.. The value appears strong and on an upward trend. It has increased from 549.00 Cr. (Mar 2024) to 578.00 Cr., marking an increase of 29.00 Cr..
• For Borrowings, as of Mar 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 5.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 312.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 266.00 Cr. (Mar 2024) to 312.00 Cr., marking an increase of 46.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 932.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 852.00 Cr. (Mar 2024) to 932.00 Cr., marking an increase of 80.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 137.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2024) to 137.00 Cr., marking a decrease of 3.00 Cr..
• For CWIP, as of Mar 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 50.00 Cr., marking an increase of 44.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 745.00 Cr.. The value appears strong and on an upward trend. It has increased from 706.00 Cr. (Mar 2024) to 745.00 Cr., marking an increase of 39.00 Cr..
• For Total Assets, as of Mar 2025, the value is 932.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Mar 2024) to 932.00 Cr., marking an increase of 80.00 Cr..

Notably, the Reserves (578.00 Cr.) exceed the Borrowings (11.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Ingersoll-Rand (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 84.74. This value is within the healthy range. It has increased from 70.45 (Mar 24) to 84.74, marking an increase of 14.29.
• For Diluted EPS (Rs.), as of Mar 25, the value is 84.74. This value is within the healthy range. It has increased from 70.45 (Mar 24) to 84.74, marking an increase of 14.29.
• For Cash EPS (Rs.), as of Mar 25, the value is 90.15. This value is within the healthy range. It has increased from 76.06 (Mar 24) to 90.15, marking an increase of 14.09.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 193.02. It has increased from 183.82 (Mar 24) to 193.02, marking an increase of 9.20.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 193.02. It has increased from 183.82 (Mar 24) to 193.02, marking an increase of 9.20.
• For Dividend / Share (Rs.), as of Mar 25, the value is 80.00. This value exceeds the healthy maximum of 3. It has increased from 70.00 (Mar 24) to 80.00, marking an increase of 10.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 423.31. It has increased from 384.47 (Mar 24) to 423.31, marking an increase of 38.84.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 119.99. This value is within the healthy range. It has increased from 100.69 (Mar 24) to 119.99, marking an increase of 19.30.
• For PBIT / Share (Rs.), as of Mar 25, the value is 114.58. This value is within the healthy range. It has increased from 95.07 (Mar 24) to 114.58, marking an increase of 19.51.
• For PBT / Share (Rs.), as of Mar 25, the value is 114.15. This value is within the healthy range. It has increased from 94.41 (Mar 24) to 114.15, marking an increase of 19.74.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 84.74. This value is within the healthy range. It has increased from 70.45 (Mar 24) to 84.74, marking an increase of 14.29.
• For PBDIT Margin (%), as of Mar 25, the value is 28.34. This value is within the healthy range. It has increased from 26.18 (Mar 24) to 28.34, marking an increase of 2.16.
• For PBIT Margin (%), as of Mar 25, the value is 27.06. This value exceeds the healthy maximum of 20. It has increased from 24.72 (Mar 24) to 27.06, marking an increase of 2.34.
• For PBT Margin (%), as of Mar 25, the value is 26.96. This value is within the healthy range. It has increased from 24.55 (Mar 24) to 26.96, marking an increase of 2.41.
• For Net Profit Margin (%), as of Mar 25, the value is 20.01. This value exceeds the healthy maximum of 10. It has increased from 18.32 (Mar 24) to 20.01, marking an increase of 1.69.
• For Return on Networth / Equity (%), as of Mar 25, the value is 43.90. This value is within the healthy range. It has increased from 38.32 (Mar 24) to 43.90, marking an increase of 5.58.
• For Return on Capital Employeed (%), as of Mar 25, the value is 57.88. This value is within the healthy range. It has increased from 50.66 (Mar 24) to 57.88, marking an increase of 7.22.
• For Return On Assets (%), as of Mar 25, the value is 28.70. This value is within the healthy range. It has increased from 26.09 (Mar 24) to 28.70, marking an increase of 2.61.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.50. It has increased from 1.42 (Mar 24) to 1.50, marking an increase of 0.08.
• For Current Ratio (X), as of Mar 25, the value is 2.30. This value is within the healthy range. It has decreased from 2.57 (Mar 24) to 2.30, marking a decrease of 0.27.
• For Quick Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.73, marking a decrease of 0.16.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.68. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 7.68, marking an increase of 0.47.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 88.50. This value exceeds the healthy maximum of 50. It has decreased from 99.36 (Mar 24) to 88.50, marking a decrease of 10.86.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 83.19. This value exceeds the healthy maximum of 50. It has decreased from 92.02 (Mar 24) to 83.19, marking a decrease of 8.83.
• For Earning Retention Ratio (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 40. It has increased from 0.64 (Mar 24) to 11.50, marking an increase of 10.86.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 16.81. This value is below the healthy minimum of 40. It has increased from 7.98 (Mar 24) to 16.81, marking an increase of 8.83.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 277.81. This value is within the healthy range. It has increased from 153.65 (Mar 24) to 277.81, marking an increase of 124.16.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 197.22. This value is within the healthy range. It has increased from 108.51 (Mar 24) to 197.22, marking an increase of 88.71.
• For Enterprise Value (Cr.), as of Mar 25, the value is 11,077.68. It has decreased from 11,334.60 (Mar 24) to 11,077.68, marking a decrease of 256.92.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.29. This value exceeds the healthy maximum of 3. It has decreased from 9.34 (Mar 24) to 8.29, marking a decrease of 1.05.
• For EV / EBITDA (X), as of Mar 25, the value is 29.25. This value exceeds the healthy maximum of 15. It has decreased from 35.66 (Mar 24) to 29.25, marking a decrease of 6.41.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.45. This value exceeds the healthy maximum of 3. It has decreased from 9.52 (Mar 24) to 8.45, marking a decrease of 1.07.
• For Retention Ratios (%), as of Mar 25, the value is 11.49. This value is below the healthy minimum of 30. It has increased from 0.63 (Mar 24) to 11.49, marking an increase of 10.86.
• For Price / BV (X), as of Mar 25, the value is 18.53. This value exceeds the healthy maximum of 3. It has decreased from 19.92 (Mar 24) to 18.53, marking a decrease of 1.39.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.45. This value exceeds the healthy maximum of 3. It has decreased from 9.52 (Mar 24) to 8.45, marking a decrease of 1.07.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness